Annual EBIT
-$51.92 M
-$17.82 M-52.24%
31 December 2023
Summary:
Actinium Pharmaceuticals annual earnings before interest & taxes is currently -$51.92 million, with the most recent change of -$17.82 million (-52.24%) on 31 December 2023. During the last 3 years, it has fallen by -$26.96 million (-107.98%). ATNM annual EBIT is now -625642.17% below its all-time high of $8300.00, reached on 31 December 2010.ATNM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBIT
-$12.60 M
-$183.00 K-1.47%
30 September 2024
Summary:
Actinium Pharmaceuticals quarterly earnings before interest & taxes is currently -$12.60 million, with the most recent change of -$183.00 thousand (-1.47%) on 30 September 2024. Over the past year, it has dropped by -$2.26 million (-21.83%). ATNM quarterly EBIT is now -458.48% below its all-time high of $3.52 million, reached on 30 June 2014.ATNM Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBIT
-$44.96 M
+$1.75 M+3.75%
30 September 2024
Summary:
Actinium Pharmaceuticals TTM earnings before interest & taxes is currently -$44.96 million, with the most recent change of +$1.75 million (+3.75%) on 30 September 2024. Over the past year, it has increased by +$6.96 million (+13.41%). ATNM TTM EBIT is now -103692.17% below its all-time high of $43.40 thousand, reached on 30 September 2011.ATNM TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ATNM EBIT Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | -21.8% | +13.4% |
| 3 y3 years | -108.0% | -56.6% | -80.1% |
| 5 y5 years | -135.2% | -171.9% | -103.7% |
ATNM EBIT High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -108.0% | at low | -144.0% | +19.4% | -81.6% | +15.0% |
| 5 y | 5 years | -135.2% | at low | -171.9% | +19.4% | -118.3% | +15.0% |
| alltime | all time | <-9999.0% | at low | -458.5% | +24.5% | <-9999.0% | +15.0% |
Actinium Pharmaceuticals EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$12.60 M(+1.5%) | -$44.96 M(-3.7%) |
| June 2024 | - | -$12.42 M(+29.4%) | -$46.71 M(-6.5%) |
| Mar 2024 | - | -$9.60 M(-7.2%) | -$49.93 M(-3.8%) |
| Dec 2023 | -$51.92 M(+52.2%) | -$10.34 M(-27.9%) | -$51.92 M(-1.8%) |
| Sept 2023 | - | -$14.35 M(-8.3%) | -$52.87 M(+9.4%) |
| June 2023 | - | -$15.64 M(+35.0%) | -$48.32 M(+19.2%) |
| Mar 2023 | - | -$11.58 M(+2.6%) | -$40.52 M(+18.8%) |
| Dec 2022 | -$34.10 M(+36.6%) | -$11.29 M(+15.2%) | -$34.10 M(+10.5%) |
| Sept 2022 | - | -$9.80 M(+24.8%) | -$30.86 M(+12.1%) |
| June 2022 | - | -$7.85 M(+52.0%) | -$27.53 M(+11.2%) |
| Mar 2022 | - | -$5.16 M(-35.8%) | -$24.76 M(-0.8%) |
| Dec 2021 | -$24.96 M(+11.5%) | -$8.05 M(+24.4%) | -$24.96 M(+6.9%) |
| Sept 2021 | - | -$6.47 M(+27.5%) | -$23.35 M(+3.8%) |
| June 2021 | - | -$5.08 M(-5.5%) | -$22.50 M(+1.9%) |
| Mar 2021 | - | -$5.37 M(-16.5%) | -$22.08 M(-1.4%) |
| Dec 2020 | -$22.39 M(+1.5%) | -$6.43 M(+14.6%) | -$22.39 M(+8.7%) |
| Sept 2020 | - | -$5.61 M(+20.4%) | -$20.59 M(-4.8%) |
| June 2020 | - | -$4.66 M(-18.0%) | -$21.63 M(-1.9%) |
| Mar 2020 | - | -$5.68 M(+22.6%) | -$22.05 M(-0.1%) |
| Dec 2019 | -$22.07 M(-7.4%) | -$4.63 M(-30.3%) | -$22.07 M(-7.3%) |
| Sept 2019 | - | -$6.65 M(+30.8%) | -$23.80 M(+1.9%) |
| June 2019 | - | -$5.09 M(-10.8%) | -$23.35 M(+0.7%) |
| Mar 2019 | - | -$5.70 M(-10.4%) | -$23.17 M(-2.7%) |
| Dec 2018 | -$23.83 M(-11.5%) | -$6.36 M(+2.7%) | -$23.83 M(+5.1%) |
| Sept 2018 | - | -$6.20 M(+26.1%) | -$22.67 M(-2.1%) |
| June 2018 | - | -$4.91 M(-22.7%) | -$23.17 M(-9.0%) |
| Mar 2018 | - | -$6.35 M(+22.0%) | -$25.46 M(-5.4%) |
| Dec 2017 | -$26.91 M(+10.7%) | -$5.21 M(-22.2%) | -$26.91 M(-5.2%) |
| Sept 2017 | - | -$6.70 M(-7.1%) | -$28.40 M(+0.3%) |
| June 2017 | - | -$7.20 M(-7.7%) | -$28.30 M(+2.1%) |
| Mar 2017 | - | -$7.81 M(+16.6%) | -$27.72 M(+14.0%) |
| Dec 2016 | -$24.32 M(+15.7%) | -$6.70 M(+1.5%) | -$24.32 M(+0.6%) |
| Sept 2016 | - | -$6.60 M(-0.4%) | -$24.16 M(+12.3%) |
| June 2016 | - | -$6.62 M(+50.5%) | -$21.51 M(-3.8%) |
| Mar 2016 | - | -$4.40 M(-32.7%) | -$22.35 M(+6.3%) |
| Dec 2015 | -$21.02 M | -$6.54 M(+65.8%) | -$21.02 M(+5.6%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2015 | - | -$3.95 M(-47.1%) | -$19.90 M(-9.7%) |
| June 2015 | - | -$7.46 M(+143.1%) | -$22.03 M(+99.3%) |
| Mar 2015 | - | -$3.07 M(-43.4%) | -$11.06 M(-55.2%) |
| Dec 2014 | -$24.69 M(+129.2%) | -$5.43 M(-10.7%) | -$24.69 M(-1.8%) |
| Sept 2014 | - | -$6.08 M(-272.9%) | -$25.14 M(+22.7%) |
| June 2014 | - | $3.52 M(-121.0%) | -$20.48 M(-23.5%) |
| Mar 2014 | - | -$16.70 M(+184.0%) | -$26.78 M(+148.6%) |
| Dec 2013 | -$10.77 M(+48.3%) | -$5.88 M(+314.2%) | -$10.77 M(+41.3%) |
| Sept 2013 | - | -$1.42 M(-49.0%) | -$7.62 M(-14.3%) |
| June 2013 | - | -$2.78 M(+304.3%) | -$8.90 M(+21.0%) |
| Mar 2013 | - | -$688.50 K(-74.8%) | -$7.35 M(+1.3%) |
| Dec 2012 | -$7.26 M(+122.1%) | -$2.73 M(+1.4%) | -$7.26 M(-7.1%) |
| Sept 2012 | - | -$2.69 M(+116.9%) | -$7.82 M(+52.5%) |
| June 2012 | - | -$1.24 M(+108.4%) | -$5.13 M(+32.7%) |
| Mar 2012 | - | -$596.00 K(-81.9%) | -$3.86 M(+18.1%) |
| Dec 2011 | -$3.27 M(<-9900.0%) | -$3.29 M(>+9900.0%) | -$3.27 M(-7633.9%) |
| Sept 2011 | - | -$2400.00(-111.1%) | $43.40 K(+15.1%) |
| June 2011 | - | $21.60 K(-900.0%) | $37.70 K(+211.6%) |
| Mar 2011 | - | -$2700.00(-110.0%) | $12.10 K(+45.8%) |
| Dec 2010 | $8300.00(-152.2%) | $26.90 K(-432.1%) | $8300.00(-131.4%) |
| Sept 2010 | - | -$8100.00(+102.5%) | -$26.40 K(+28.8%) |
| June 2010 | - | -$4000.00(-38.5%) | -$20.50 K(+10.2%) |
| Mar 2010 | - | -$6500.00(-16.7%) | -$18.60 K(+16.3%) |
| Dec 2009 | -$15.90 K(-39.5%) | -$7800.00(+254.5%) | -$16.00 K(+11.1%) |
| Sept 2009 | - | -$2200.00(+4.8%) | -$14.40 K(+0.7%) |
| June 2009 | - | -$2100.00(-46.2%) | -$14.30 K(-30.2%) |
| Mar 2009 | - | -$3900.00(-37.1%) | -$20.50 K(-22.1%) |
| Dec 2008 | -$26.30 K(+22.3%) | -$6200.00(+195.2%) | -$26.30 K(-22.9%) |
| Sept 2008 | - | -$2100.00(-74.7%) | -$34.10 K(-7.1%) |
| June 2008 | - | -$8300.00(-14.4%) | -$36.70 K(+17.6%) |
| Mar 2008 | - | -$9700.00(-30.7%) | -$31.20 K(+45.1%) |
| Dec 2007 | -$21.50 K(+22.9%) | -$14.00 K(+197.9%) | -$21.50 K(+43.3%) |
| Sept 2007 | - | -$4700.00(+67.9%) | -$15.00 K(-26.1%) |
| June 2007 | - | -$2800.00(<-9900.0%) | -$20.30 K(+16.0%) |
| Mar 2007 | - | $0.00(-100.0%) | -$17.50 K(0.0%) |
| Dec 2006 | -$17.50 K | -$7500.00(-25.0%) | -$17.50 K(+75.0%) |
| Sept 2006 | - | -$10.00 K | -$10.00 K |
FAQ
- What is Actinium Pharmaceuticals annual earnings before interest & taxes?
- What is the all time high annual EBIT for Actinium Pharmaceuticals?
- What is Actinium Pharmaceuticals quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Actinium Pharmaceuticals?
- What is Actinium Pharmaceuticals quarterly EBIT year-on-year change?
- What is Actinium Pharmaceuticals TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Actinium Pharmaceuticals?
- What is Actinium Pharmaceuticals TTM EBIT year-on-year change?
What is Actinium Pharmaceuticals annual earnings before interest & taxes?
The current annual EBIT of ATNM is -$51.92 M
What is the all time high annual EBIT for Actinium Pharmaceuticals?
Actinium Pharmaceuticals all-time high annual earnings before interest & taxes is $8300.00
What is Actinium Pharmaceuticals quarterly earnings before interest & taxes?
The current quarterly EBIT of ATNM is -$12.60 M
What is the all time high quarterly EBIT for Actinium Pharmaceuticals?
Actinium Pharmaceuticals all-time high quarterly earnings before interest & taxes is $3.52 M
What is Actinium Pharmaceuticals quarterly EBIT year-on-year change?
Over the past year, ATNM quarterly earnings before interest & taxes has changed by -$2.26 M (-21.83%)
What is Actinium Pharmaceuticals TTM earnings before interest & taxes?
The current TTM EBIT of ATNM is -$44.96 M
What is the all time high TTM EBIT for Actinium Pharmaceuticals?
Actinium Pharmaceuticals all-time high TTM earnings before interest & taxes is $43.40 K
What is Actinium Pharmaceuticals TTM EBIT year-on-year change?
Over the past year, ATNM TTM earnings before interest & taxes has changed by +$6.96 M (+13.41%)